Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma
Article first published online: 19 DEC 2008
© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Limited
Volume 54, Issue 2, pages 214–220, January 2009
How to Cite
Liu, T.-Y., Chen, C.-Y., Tien, H.-F. and Lin, C.-W. (2009), Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma. Histopathology, 54: 214–220. doi: 10.1111/j.1365-2559.2008.03199.x
- Issue published online: 26 JAN 2009
- Article first published online: 19 DEC 2008
- Date of submission 2 June 2008 Accepted for publication 29 July 2008
Aims: Loss of CD7 is characteristic of adult T-cell lymphoma/leukaemia (ATLL). Galectin-3 (Gal-3) is strongly induced in cultured human T lymphotropic virus-1-infected T lymphocytes, and may cause apoptosis through interaction with CD7. The aim was to investigate the clinical relevance of the Gal-3–CD7 pathway in ATLL.
Methods and results: Immunohistochemistry for Gal-3 and CD7 was performed on 22 cases of ATLL in the leukaemic phase. We found that the lymphoma cells were not necessarily Gal-3+, but Gal-3+ stromal cells could always be found. Independent of the status of Gal-3, there was an association of loss of CD7 with a worse prognosis.
Conclusions: These data suggest that, by down-regulating CD7, ATLL cells could have escaped Gal-3-induced apoptosis to run a more aggressive clinical course.